WuXi Biologics ,a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year the company has scored among the highest in ESG Risk Ratings.
Sustainalytics, a leading ESG data, research, and ratings firm, supports global investors with the development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings cover more than 15,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements. WuXi Biologics ranks in the top 1% of companies assessed in the pharmaceutical industry.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to once again receive this honor from Morningstar Sustainalytics. It is a reflection and recognition of our ongoing commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we consistently deliver our own ESG excellence while enabling partners worldwide to fulfill their ESG commitments, jointly working with all stakeholders to promote responsible practices throughout the entire value chain."
In recent years, WuXi Biologics' ESG strategy and initiatives have made significant progress and gained widespread recognition. The Company was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
Comments powered by CComment